Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer

Eishi Baba, Hiromitsu Fujishima, Hitoshi Kusaba, Taito Esaki, hiroshi ariyama, Ken Kato, Risa Tanaka, Kenji Mitsugi, Yoshihiro Shibata, Mine Harada, Shuji Nakano

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

The combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been reported to be active against metastatic gastric cancer (MGC) and great synergy has been shown in vivo and in vitro when 5-FU precedes CDDP. The sequential combination of S-1 (tegafur, oxonic acid, 5-chloro-2,4-dihydroxypyridine) followed by CDDP for MGC was investigated. A phase I trial applying increasing doses of oral administration of S-1 (65-80 mg/m2) for 21 days and increasing doses of CDDP (60-80 mg/m2) on day 22 every 35 days was conducted in order to determine the maximum tolerated dose (MTD) and recommended phase II dose. Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study. Three patients were treated at each dose level with escalation based on toxicity. Fifteen patients were included and evaluated for dose-limiting toxicity (DLT) and MTD. DLT included NCICTC grade 3 anorexia and fatigue in patients treated at S-1 80 mg/m2 and CDDP 80 mg/m2 (dose level 5). The other toxicities, grade 3 or higher, included neutropenia (grade 3) and nausea/vomiting (grade 3). Non-hematological toxicities were grade 1/2 and included diarrhea, nausea and stomatitis. There was no treatment-related mortality. Therefore, the recommended dose was a combination of S-1 at 80 mg/m2 and CDDP at 70 mg/m2. This sequential administration of S-1 and CDDP every 35 days is tolerable and warrants a phase II trial. A multicenter phase II study is currently under way.

元の言語英語
ページ(範囲)1727-1732
ページ数6
ジャーナルAnticancer Research
29
発行部数5
出版物ステータス出版済み - 5 1 2009

Fingerprint

Cisplatin
Stomach Neoplasms
Maximum Tolerated Dose
Fluorouracil
Nausea
Oxonic Acid
Tegafur
Stomatitis
Anorexia
Neutropenia
Vomiting
Fatigue
Oral Administration
Diarrhea
Drug Therapy
Mortality
S 1 (combination)
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. / Baba, Eishi; Fujishima, Hiromitsu; Kusaba, Hitoshi; Esaki, Taito; ariyama, hiroshi; Kato, Ken; Tanaka, Risa; Mitsugi, Kenji; Shibata, Yoshihiro; Harada, Mine; Nakano, Shuji.

:: Anticancer Research, 巻 29, 番号 5, 01.05.2009, p. 1727-1732.

研究成果: ジャーナルへの寄稿記事

Baba, E, Fujishima, H, Kusaba, H, Esaki, T, ariyama, H, Kato, K, Tanaka, R, Mitsugi, K, Shibata, Y, Harada, M & Nakano, S 2009, 'Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer', Anticancer Research, 巻. 29, 番号 5, pp. 1727-1732.
Baba, Eishi ; Fujishima, Hiromitsu ; Kusaba, Hitoshi ; Esaki, Taito ; ariyama, hiroshi ; Kato, Ken ; Tanaka, Risa ; Mitsugi, Kenji ; Shibata, Yoshihiro ; Harada, Mine ; Nakano, Shuji. / Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. :: Anticancer Research. 2009 ; 巻 29, 番号 5. pp. 1727-1732.
@article{87ee20dcc3384daca9cb92d71b5d244f,
title = "Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer",
abstract = "The combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been reported to be active against metastatic gastric cancer (MGC) and great synergy has been shown in vivo and in vitro when 5-FU precedes CDDP. The sequential combination of S-1 (tegafur, oxonic acid, 5-chloro-2,4-dihydroxypyridine) followed by CDDP for MGC was investigated. A phase I trial applying increasing doses of oral administration of S-1 (65-80 mg/m2) for 21 days and increasing doses of CDDP (60-80 mg/m2) on day 22 every 35 days was conducted in order to determine the maximum tolerated dose (MTD) and recommended phase II dose. Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study. Three patients were treated at each dose level with escalation based on toxicity. Fifteen patients were included and evaluated for dose-limiting toxicity (DLT) and MTD. DLT included NCICTC grade 3 anorexia and fatigue in patients treated at S-1 80 mg/m2 and CDDP 80 mg/m2 (dose level 5). The other toxicities, grade 3 or higher, included neutropenia (grade 3) and nausea/vomiting (grade 3). Non-hematological toxicities were grade 1/2 and included diarrhea, nausea and stomatitis. There was no treatment-related mortality. Therefore, the recommended dose was a combination of S-1 at 80 mg/m2 and CDDP at 70 mg/m2. This sequential administration of S-1 and CDDP every 35 days is tolerable and warrants a phase II trial. A multicenter phase II study is currently under way.",
author = "Eishi Baba and Hiromitsu Fujishima and Hitoshi Kusaba and Taito Esaki and hiroshi ariyama and Ken Kato and Risa Tanaka and Kenji Mitsugi and Yoshihiro Shibata and Mine Harada and Shuji Nakano",
year = "2009",
month = "5",
day = "1",
language = "English",
volume = "29",
pages = "1727--1732",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer

AU - Baba, Eishi

AU - Fujishima, Hiromitsu

AU - Kusaba, Hitoshi

AU - Esaki, Taito

AU - ariyama, hiroshi

AU - Kato, Ken

AU - Tanaka, Risa

AU - Mitsugi, Kenji

AU - Shibata, Yoshihiro

AU - Harada, Mine

AU - Nakano, Shuji

PY - 2009/5/1

Y1 - 2009/5/1

N2 - The combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been reported to be active against metastatic gastric cancer (MGC) and great synergy has been shown in vivo and in vitro when 5-FU precedes CDDP. The sequential combination of S-1 (tegafur, oxonic acid, 5-chloro-2,4-dihydroxypyridine) followed by CDDP for MGC was investigated. A phase I trial applying increasing doses of oral administration of S-1 (65-80 mg/m2) for 21 days and increasing doses of CDDP (60-80 mg/m2) on day 22 every 35 days was conducted in order to determine the maximum tolerated dose (MTD) and recommended phase II dose. Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study. Three patients were treated at each dose level with escalation based on toxicity. Fifteen patients were included and evaluated for dose-limiting toxicity (DLT) and MTD. DLT included NCICTC grade 3 anorexia and fatigue in patients treated at S-1 80 mg/m2 and CDDP 80 mg/m2 (dose level 5). The other toxicities, grade 3 or higher, included neutropenia (grade 3) and nausea/vomiting (grade 3). Non-hematological toxicities were grade 1/2 and included diarrhea, nausea and stomatitis. There was no treatment-related mortality. Therefore, the recommended dose was a combination of S-1 at 80 mg/m2 and CDDP at 70 mg/m2. This sequential administration of S-1 and CDDP every 35 days is tolerable and warrants a phase II trial. A multicenter phase II study is currently under way.

AB - The combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been reported to be active against metastatic gastric cancer (MGC) and great synergy has been shown in vivo and in vitro when 5-FU precedes CDDP. The sequential combination of S-1 (tegafur, oxonic acid, 5-chloro-2,4-dihydroxypyridine) followed by CDDP for MGC was investigated. A phase I trial applying increasing doses of oral administration of S-1 (65-80 mg/m2) for 21 days and increasing doses of CDDP (60-80 mg/m2) on day 22 every 35 days was conducted in order to determine the maximum tolerated dose (MTD) and recommended phase II dose. Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study. Three patients were treated at each dose level with escalation based on toxicity. Fifteen patients were included and evaluated for dose-limiting toxicity (DLT) and MTD. DLT included NCICTC grade 3 anorexia and fatigue in patients treated at S-1 80 mg/m2 and CDDP 80 mg/m2 (dose level 5). The other toxicities, grade 3 or higher, included neutropenia (grade 3) and nausea/vomiting (grade 3). Non-hematological toxicities were grade 1/2 and included diarrhea, nausea and stomatitis. There was no treatment-related mortality. Therefore, the recommended dose was a combination of S-1 at 80 mg/m2 and CDDP at 70 mg/m2. This sequential administration of S-1 and CDDP every 35 days is tolerable and warrants a phase II trial. A multicenter phase II study is currently under way.

UR - http://www.scopus.com/inward/record.url?scp=67650091229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650091229&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1727

EP - 1732

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -